{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:57:12Z","timestamp":1793451432832,"version":"4.5.0"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13346-025-01965-y","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:04:13Z","timestamp":1757181853000},"page":"4479-4500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus"],"prefix":"10.1007","volume":"15","author":[{"given":"Riti","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal Sangita Babasaheb","family":"Galave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-869X","authenticated-orcid":false,"given":"Anil B.","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"1965_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01951-9","author":"X Lu","year":"2024","unstructured":"Lu X, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Dec 01. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01951-9","journal-title":"Dec 01"},{"key":"1965_CR2","doi-asserted-by":"crossref","unstructured":"Plows SJBPRCVMH. JF, The pathophysiology of gestational diabetes mellitus. Int J Mol Sci, 2018.","DOI":"10.3390\/ijms19113342"},{"key":"1965_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Publishing Group. 2018. https:\/\/doi.org\/10.1038\/nrendo.2017.151","journal-title":"Nat Publishing Group"},{"key":"1965_CR4","doi-asserted-by":"publisher","unstructured":"Cho NH, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. Apr. 2018;138:271\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"1965_CR5","doi-asserted-by":"publisher","unstructured":"Classification and diagnosis of diabetes. Standards of medical care in Diabetes-2020. Diabetes Care. Jan. 2020;43:S14\u201331. https:\/\/doi.org\/10.2337\/dc20-S002","DOI":"10.2337\/dc20-S002"},{"key":"1965_CR6","doi-asserted-by":"publisher","unstructured":"Powers MA et al. Jul., Diabetes Self-management Education and Support in Adults with Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association, Diabetes Care, vol. 43, no. 7, pp. 1636\u20131649, 2020, https:\/\/doi.org\/10.2337\/dci20-0023","DOI":"10.2337\/dci20-0023"},{"key":"1965_CR7","unstructured":"Goyal SMJI. R, Type 2 diabetes. StatPearls Publishing; 2025."},{"key":"1965_CR8","unstructured":"L.-S. A. S. B-VAJS H. U. K. O. H. M. C., Galicia-Garcia U. Pathophysiology of Type 2 Diabetes Mellitus., Int J Mol Sci, 2020."},{"key":"1965_CR9","unstructured":"Federation ID. IDF Diabetes Atlas, 10th edn., Brussels, Belgium: 2021. Available at: https:\/\/www.diabetesatlas.org"},{"key":"1965_CR10","doi-asserted-by":"crossref","unstructured":"Minal DATASMH, Patel R. Economic burden, financial stress, and cost-related coping among people with uncontrolled diabetes in the U.S. Prev Med Rep, 34, 2023.","DOI":"10.1016\/j.pmedr.2023.102246"},{"key":"1965_CR11","unstructured":"Ganesan RMSS. K, Oral Hypoglycemic Medications. 2025."},{"key":"1965_CR12","unstructured":"Feingold KR, et al. editors. Oral and injectable (Non-Insulin) Pharmacological agents for the treatment of type 2 diabetes., South Dartmouth (MA): MDText.com, Inc."},{"key":"1965_CR13","doi-asserted-by":"publisher","unstructured":"Davies MJ et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD), dec. 01, 2018. Am Diabetes Association Inc https:\/\/doi.org\/10.2337\/dci18-0033","DOI":"10.2337\/dci18-0033"},{"key":"1965_CR14","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. Jul. 2015;1. https:\/\/doi.org\/10.1038\/nrdp.2015.19","DOI":"10.1038\/nrdp.2015.19"},{"key":"1965_CR15","doi-asserted-by":"publisher","unstructured":"Chaudhury A, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). Jan. 2017;8. https:\/\/doi.org\/10.3389\/fendo.2017.00006","DOI":"10.3389\/fendo.2017.00006"},{"key":"1965_CR16","unstructured":"Cerillo PM. JL, Liraglutide. StatPearls Publishing; 2024."},{"key":"1965_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Media S A. 2019. https:\/\/doi.org\/10.3389\/fendo.2019.00155","journal-title":"Front Media S A"},{"key":"1965_CR18","doi-asserted-by":"publisher","unstructured":"Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. Sep. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","DOI":"10.1038\/s41392-024-01931-z"},{"key":"1965_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1398059","author":"R Tamayo-Trujillo","year":"2024","unstructured":"Tamayo-Trujillo R, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Media SA. 2024. https:\/\/doi.org\/10.3389\/fnut.2024.1398059","journal-title":"Front Media SA"},{"key":"1965_CR20","doi-asserted-by":"crossref","unstructured":"Knudsen NPHP. LB, Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration., J Med Chem., 2000.","DOI":"10.1021\/jm9909645"},{"key":"1965_CR21","doi-asserted-by":"crossref","unstructured":"Mahapatra KMSBM. MK, Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord, 2022.","DOI":"10.1007\/s11154-021-09699-1"},{"key":"1965_CR22","unstructured":"The Business Research Company. Liraglutide Market Report 2024."},{"key":"1965_CR23","unstructured":"Roots analysis. -Business research and consulting, GLP-1 Market."},{"key":"1965_CR24","unstructured":"Food US, Administration D. FDA approves first generic of Once-Daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes."},{"key":"1965_CR25","doi-asserted-by":"crossref","unstructured":"Anil ARBSSDRDB, Jindal B. Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Adv Drug Deliv Rev, 198, 2023.","DOI":"10.1016\/j.addr.2023.114862"},{"key":"1965_CR26","doi-asserted-by":"crossref","unstructured":"Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab, 2013.","DOI":"10.4103\/2230-8210.111625"},{"key":"1965_CR27","unstructured":"Collins CR. L, Glucagon-Like Peptide-1 receptor agonists, StatPearls Publishing LLC."},{"key":"1965_CR28","doi-asserted-by":"publisher","unstructured":"Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Apr. 03, 2018, Cell Press. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"1965_CR29","doi-asserted-by":"crossref","unstructured":"0rskov C, Holst JJ, Nielsen V. Effect of truncated Glucagon-Like Peptide-1 [Proglucagon-(78\u2013107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach, 2009.","DOI":"10.1210\/endo-123-4-2009"},{"key":"1965_CR30","doi-asserted-by":"publisher","unstructured":"Vilsb\u00f8ll T, Agers\u00f8 H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. Jan. 2003;88(1):220\u20134. https:\/\/doi.org\/10.1210\/jc.2002-021053","DOI":"10.1210\/jc.2002-021053"},{"key":"1965_CR31","doi-asserted-by":"crossref","unstructured":"K. HBKL, Adelhorst O. K, Structure-activity studies of glucagon-like peptide-1. J Biol Chem, 1994.","DOI":"10.1016\/S0021-9258(17)37366-0"},{"key":"1965_CR32","doi-asserted-by":"crossref","unstructured":"Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol, 2012.","DOI":"10.1111\/j.1476-5381.2011.01687.x"},{"key":"1965_CR33","doi-asserted-by":"publisher","unstructured":"Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. Jun. 2016;55(6):657\u201372. https:\/\/doi.org\/10.1007\/s40262-015-0343-6","DOI":"10.1007\/s40262-015-0343-6"},{"key":"1965_CR34","doi-asserted-by":"publisher","unstructured":"Malm-Erjef\u00e4lt M et al. Nov., Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase, Drug Metabolism and Disposition, vol. 38, no. 11, pp. 1944\u20131953, 2010, https:\/\/doi.org\/10.1124\/dmd.110.034066","DOI":"10.1124\/dmd.110.034066"},{"key":"1965_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","volume":"1","author":"BP Roques","year":"1993","unstructured":"Roques BP, Noble F, Daug\u00e9 V, Fourni\u00e9-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical Pharmacology. Pharmacol Rev. 1993;1:87\u2013146.","journal-title":"Pharmacol Rev"},{"key":"1965_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1152\/ajpgi.00035.2013.-Rapid","volume":"304","author":"A Plamboeck","year":"2013","unstructured":"Plamboeck A, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol. 2013;304:1117\u201327. https:\/\/doi.org\/10.1152\/ajpgi.00035.2013.-Rapid","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"11","key":"1965_CR37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/dom.12133","volume":"15","author":"K Hermansen","year":"2013","unstructured":"Hermansen K, et al. Liraglutide suppresses postprandial triglyceride and Apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15(11):1040\u20138. https:\/\/doi.org\/10.1111\/dom.12133","journal-title":"Diabetes Obes Metab"},{"key":"1965_CR38","doi-asserted-by":"crossref","unstructured":"Elbr\u00f8nd B et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like peptide 1 derivative, in healthy male subjects, 2002.","DOI":"10.2337\/diacare.25.8.1398"},{"key":"1965_CR39","doi-asserted-by":"crossref","unstructured":"Agers\u00f9 H, Jensen LB, Elbr\u00f9nd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men, 2002.","DOI":"10.1007\/s00125-001-0719-z"},{"key":"1965_CR40","doi-asserted-by":"publisher","unstructured":"Badgujar D, Bawake S, Sharma N. A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography-high resolution mass spectrometry, Journal of Peptide Science, Jan. 2024, https:\/\/doi.org\/10.1002\/psc.3652","DOI":"10.1002\/psc.3652"},{"key":"1965_CR41","unstructured":"Latif W, Lambrinos KJ, Patel P, StatPearls et al. StatPearls Publishing, 2025."},{"key":"1965_CR42","doi-asserted-by":"publisher","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. Apr. 2017;19(4):524\u201336. https:\/\/doi.org\/10.1111\/dom.12849","DOI":"10.1111\/dom.12849"},{"key":"1965_CR43","doi-asserted-by":"publisher","unstructured":"Dungan KM et al. Oct., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial, The Lancet, vol. 384, no. 9951, pp. 1349\u20131357, 2014, https:\/\/doi.org\/10.1016\/S0140-6736(14)60976-4","DOI":"10.1016\/S0140-6736(14)60976-4"},{"key":"1965_CR44","doi-asserted-by":"publisher","unstructured":"Hu EH, Tsai ML, Lin Y, Chou TS, Chen TH. A review and Meta-Analysis of the safety and efficacy of using Glucagon-like Peptide-1 receptor agonists. Mar 01 2024 Multidisciplinary Digit Publishing Inst (MDPI). https:\/\/doi.org\/10.3390\/medicina60030357","DOI":"10.3390\/medicina60030357"},{"key":"1965_CR45","unstructured":"I. K. KS, Liu YD. Y, Cardioprotective effects of GLP-1(28-36a): A degraded metabolite or GLP-1\u2019s better half? J Diabetes Investig, 2020."},{"key":"1965_CR46","doi-asserted-by":"publisher","unstructured":"Krammer T et al. Mar., Cardioprotective effects of semaglutide on isolated human ventricular myocardium., Eur J Heart Fail, 2025, https:\/\/doi.org\/10.1002\/ejhf.3644","DOI":"10.1002\/ejhf.3644"},{"key":"1965_CR47","doi-asserted-by":"publisher","unstructured":"Xie S, et al. Long-Term activation of Glucagon-like peptide-1 receptor by dulaglutide prevents diabetic heart failure and metabolic remodeling in type 2 diabetes. J Am Heart Assoc. Oct. 2022;11(19). https:\/\/doi.org\/10.1161\/JAHA.122.026728","DOI":"10.1161\/JAHA.122.026728"},{"key":"1965_CR48","unstructured":"A BSTRACT. [Online]. Available: http:\/\/www.aapsj.org"},{"key":"1965_CR49","doi-asserted-by":"publisher","unstructured":"Zapadka KL, et al. A pH-Induced switch in human Glucagon-like Peptide-1 aggregation kinetics. J Am Chem Soc. Dec. 2016;138(50):16259\u201365. https:\/\/doi.org\/10.1021\/jacs.6b05025","DOI":"10.1021\/jacs.6b05025"},{"key":"1965_CR50","doi-asserted-by":"publisher","unstructured":"Jha NN, Anoop A, Ranganathan S, Mohite GM, Padinhateeri R, Maji SK. Characterization of amyloid formation by glucagon-like peptides: Role of basic residues in heparin-mediated aggregation, Biochemistry, vol. 52, no. 49, pp. 8800\u20138810, Dec. 2013, https:\/\/doi.org\/10.1021\/bi401398k","DOI":"10.1021\/bi401398k"},{"key":"1965_CR51","doi-asserted-by":"crossref","unstructured":"Poon S, Birkett NR, Fowler SB, Luisi BF, Dobson CM, Zurdo J. Amyloidogenicity and aggregate cytotoxicity of human Glucagon-Like Peptide-1 (hGLP-1), 2009.","DOI":"10.2174\/092986609789839232"},{"key":"1965_CR52","doi-asserted-by":"publisher","unstructured":"Bothe JR, Andrews A, Smith KJ, Joyce LA, Krishnamachari Y, Kashi S. Peptide oligomerization memory effects and their impact on the physical stability of the GLP-1 agonist liraglutide. Mol Pharm. May 2019;16(5):2153\u201361. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00106","DOI":"10.1021\/acs.molpharmaceut.9b00106"},{"key":"1965_CR53","doi-asserted-by":"publisher","unstructured":"Nielsen L, et al. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry. May 2001;40:6036\u201346. https:\/\/doi.org\/10.1021\/bi002555c","DOI":"10.1021\/bi002555c"},{"key":"1965_CR54","doi-asserted-by":"publisher","unstructured":"Wang Y, Lomakin A, Kanai S, Alex R, Benedek GB. Transformation of oligomers of lipidated peptide induced by change in pH, Mol Pharm, vol. 12, no. 2, pp. 411\u2013419, Feb. 2015, https:\/\/doi.org\/10.1021\/mp500519s","DOI":"10.1021\/mp500519s"},{"key":"1965_CR55","doi-asserted-by":"publisher","unstructured":"Frederiksen TM, et al. Oligomerization of a Glucagon-like peptide 1 analog: bridging experiment and simulations. Biophys J. Sep. 2015;109(6):1202\u201313. https:\/\/doi.org\/10.1016\/j.bpj.2015.07.051","DOI":"10.1016\/j.bpj.2015.07.051"},{"key":"1965_CR56","unstructured":"ferrone1999."},{"key":"1965_CR57","doi-asserted-by":"crossref","unstructured":"Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist,., 2018. [Online]. Available: http:\/\/stm.sciencemag.org\/","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"1965_CR58","doi-asserted-by":"publisher","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Apr 01 2020 Nature Research. https:\/\/doi.org\/10.1038\/s41573-019-0053-0","DOI":"10.1038\/s41573-019-0053-0"},{"key":"1965_CR59","doi-asserted-by":"publisher","unstructured":"Shi Y et al. Feb., Oral delivery of liraglutide-loaded Poly-N-(2-hydroxypropyl) methacrylamide\/chitosan nanoparticles: Preparation, characterization, and pharmacokinetics, J Biomater Appl, vol. 35, no. 7, pp. 754\u2013761, 2021, https:\/\/doi.org\/10.1177\/0885328220947889","DOI":"10.1177\/0885328220947889"},{"key":"1965_CR60","doi-asserted-by":"publisher","unstructured":"Tsai LC, Chen CH, Lin CW, Ho YC, Mi FL. Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin, Int J Biol Macromol, vol. 126, pp. 141\u2013150, Apr. 2019, https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.12.182","DOI":"10.1016\/j.ijbiomac.2018.12.182"},{"key":"1965_CR61","doi-asserted-by":"publisher","unstructured":"Chen Y, et al. Controlled release of liraglutide using thermogelling polymers in treatment of diabetes. Sci Rep. Aug. 2016;6. https:\/\/doi.org\/10.1038\/srep31593","DOI":"10.1038\/srep31593"},{"key":"1965_CR62","doi-asserted-by":"publisher","unstructured":"Chavoshi F, Mirjalili SZ, Mohammadi A, Amini M, Somsen GW, Shirangi M. Forced degradation products of liraglutide: A comparative study of similarity between originator and analogue version by liquid Chromatography\u2013Mass spectrometry. Int J Pept Res Ther. May 2024;30(3). https:\/\/doi.org\/10.1007\/s10989-024-10608-8","DOI":"10.1007\/s10989-024-10608-8"},{"key":"1965_CR63","doi-asserted-by":"publisher","unstructured":"Fincke A, Winter J, Bunte T, Olbrich C. Thermally induced degradation pathways of three different antibody-based drug development candidates. Eur J Pharm Sci. Oct. 2014;62:148\u201360. https:\/\/doi.org\/10.1016\/j.ejps.2014.05.014","DOI":"10.1016\/j.ejps.2014.05.014"},{"key":"1965_CR64","unstructured":"Nordisk N, Leginus IJ. CHEMISTRY REVIEW NDA 206321 SaxendaTM (Liraglutide [rDNA origin] Injection) For the Division of Metabolism and Endocrinology Products CHEMISTRY REVIEW #1."},{"key":"1965_CR65","unstructured":"D. VJBVJSK G. T. S. N. B. D. S. RP., Sheikh AR. Reactivity of N terminal histidine of peptides towards excipients\/impurity of excipients: A case study of liraglutide excipient compatibility study., J Pharm Sci., 2024."},{"key":"1965_CR66","doi-asserted-by":"crossref","unstructured":"Nugrahadi HWFHSCAC. PP, Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: A review. Pharmaceutics, 2023.","DOI":"10.3390\/pharmaceutics15030935"},{"key":"1965_CR67","unstructured":"Ajit JMD et al. Reaction of a peptide with Polyvinylpyrrolidone in the solid state, 2003."},{"issue":"5","key":"1965_CR68","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1034\/j.1399-3011.2000.00783.x","volume":"56","author":"R Li","year":"2000","unstructured":"Li R, D\u2019Souza AJ, Schowen RL, Borchardt RT, Topp EM, Laird BB. Effects of solution Polarity and viscosity on peptide deamidation. J Pept Res. 2000;56(5):326\u201334. https:\/\/doi.org\/10.1034\/j.1399-3011.2000.00783.x","journal-title":"J Pept Res"},{"key":"1965_CR69","unstructured":"parkins2000."},{"key":"1965_CR70","doi-asserted-by":"crossref","unstructured":"van de Hovgaard WM. Pharmaceutical Formulation Development of Peptides and Proteins, 1st Edition. 2000.","DOI":"10.4324\/9780203484180"},{"key":"1965_CR71","doi-asserted-by":"publisher","unstructured":"Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide, Apr. 2010. https:\/\/doi.org\/10.1038\/nrd3148","DOI":"10.1038\/nrd3148"},{"key":"1965_CR72","doi-asserted-by":"crossref","unstructured":"Elsayed KTID. YY, Regulatory guidelines for the analysis of therapeutic peptides and proteins. J Pept Sci, 2025.","DOI":"10.1002\/psc.70001"},{"issue":"6","key":"1965_CR73","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jps.20365","volume":"94","author":"DK Chou","year":"2005","unstructured":"Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. Effects of tween 20\u00ae and tween 80\u00ae on the stability of Albutropin during agitation. J Pharm Sci. 2005;94(6):1368\u201381. https:\/\/doi.org\/10.1002\/jps.20365","journal-title":"J Pharm Sci"},{"key":"1965_CR74","doi-asserted-by":"publisher","unstructured":"Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr. Sep. 2009;67(5):340\u201352. https:\/\/doi.org\/10.1016\/j.pharma.2009.05.008","DOI":"10.1016\/j.pharma.2009.05.008"},{"key":"1965_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-006-0553-9","author":"G Lentzen","year":"2006","unstructured":"Lentzen G, Schwarz T. Extremolytes: natural compounds from extremophiles for versatile applications. Oct. 2006. https:\/\/doi.org\/10.1007\/s00253-006-0553-9","journal-title":"Oct"},{"key":"1965_CR76","unstructured":"Panuszko A, Bru\u017adziak P, Kaczkowska E, Stangret J. General mechanism of osmolytes\u2019 influence on Protein Stability Irrespective of the Type of Osmolyte Cosolvent."},{"key":"1965_CR77","doi-asserted-by":"crossref","unstructured":"Galinski EA, Stein M, Amendt B, Kinder M. The Kosmotropic (Structure-Forming) Effect of Compensatory Solutes, 1997.","DOI":"10.1016\/S0300-9629(96)00275-7"},{"key":"1965_CR78","doi-asserted-by":"publisher","unstructured":"Avanti C, Saluja V, Van Streun ELP, Frijlink HW, Hinrichs WLJ. Stability of lysozyme in aqueous extremolyte solutions during heat shock and accelerated thermal conditions. PLoS ONE. Jan. 2014;9(1). https:\/\/doi.org\/10.1371\/journal.pone.0086244","DOI":"10.1371\/journal.pone.0086244"},{"key":"1965_CR79","doi-asserted-by":"publisher","unstructured":"Bolen DW, Rose GD. Structure and energetics of the hydrogen-bonded backbone in protein folding, 2008. https:\/\/doi.org\/10.1146\/annurev.biochem.77.061306.131357","DOI":"10.1146\/annurev.biochem.77.061306.131357"},{"key":"1965_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03918-1","author":"A Pandey","year":"2025","unstructured":"Pandey A, Rath G, Chawala R, Goyal AK. A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide. Springer Sci Bus Media Deutschland GmbH. 2025. https:\/\/doi.org\/10.1007\/s00210-025-03918-1","journal-title":"Springer Sci Bus Media Deutschland GmbH"},{"key":"1965_CR81","doi-asserted-by":"crossref","unstructured":"Ayhan T\u00d6TSBT. I, Injection site reaction induced by liraglutide use in a female patient with obesity. JCEM Case Rep, 2023.","DOI":"10.1210\/jcemcr\/luac014.039"},{"key":"1965_CR82","unstructured":"U. I. AW, Q. OMOSSZA, Din FU. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed, 2017."},{"key":"1965_CR83","doi-asserted-by":"publisher","unstructured":"Din FU et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Oct 05 2017 Dove Med Press Ltd https:\/\/doi.org\/10.2147\/IJN.S146315","DOI":"10.2147\/IJN.S146315"},{"key":"1965_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2009.04.008","author":"B Mishra","year":"2010","unstructured":"Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Elsevier Inc. 2010. https:\/\/doi.org\/10.1016\/j.nano.2009.04.008","journal-title":"Elsevier Inc"},{"key":"1965_CR85","doi-asserted-by":"publisher","unstructured":"How CW, Rasedee A, Manickam S, Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity, Colloids Surf B Biointerfaces, vol. 112, pp. 393\u2013399, Dec. 2013, https:\/\/doi.org\/10.1016\/j.colsurfb.2013.08.009","DOI":"10.1016\/j.colsurfb.2013.08.009"},{"key":"1965_CR86","doi-asserted-by":"publisher","unstructured":"Jakhar DK, et al. Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials. Int J Pharm. Mar. 2023;634. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122585","DOI":"10.1016\/j.ijpharm.2023.122585"},{"key":"1965_CR87","doi-asserted-by":"crossref","unstructured":"Luo YCFYM. XM, Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis. Adv Drug Deliv Rev, 2021.","DOI":"10.1016\/j.addr.2021.01.004"},{"key":"1965_CR88","doi-asserted-by":"crossref","unstructured":"Murat Yanat KS. Preparation methods and applications of Chitosan nanoparticles; with an outlook toward reinforcement of biodegradable packaging. React Funct Polym, 161, 2021.","DOI":"10.1016\/j.reactfunctpolym.2021.104849"},{"key":"1965_CR89","doi-asserted-by":"crossref","unstructured":"van der Jerome E, Paques P. Preparation methods of alginate nanoparticles. Adv Colloid Interface Sci, 209, 2014.","DOI":"10.1016\/j.cis.2014.03.009"},{"key":"1965_CR90","doi-asserted-by":"crossref","unstructured":"Madkhali OA. Drug delivery of gelatin nanoparticles as a biodegradable polymer for the treatment of infectious diseases: perspectives and challenges. Polym (Basel), 2023.","DOI":"10.3390\/polym15214327"},{"key":"1965_CR91","unstructured":"R. J. U. W. E. P. N. V. O. B. K. W. P. JH. Rao NV, hyaluronic acid nanoparticles as nanomedicine for treatment of inflammatory diseases. Pharmaceutics, 2020."},{"key":"1965_CR92","unstructured":"K. A. A. N-K. Y. M. M. M. Z. N. Z. V. R. A. A. S. H. Y. J. SW. Sadat Tabatabaei Mirakabad F, PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev., 2014."},{"key":"1965_CR93","doi-asserted-by":"crossref","unstructured":"D.-W. MABEFE, \u0141ukasiewicz M. S, Polycaprolactone nanoparticles as promising candidates for nanocarriers in novel nanomedicines. Pharmaceutics, 2021.","DOI":"10.3390\/pharmaceutics13020191"},{"key":"1965_CR94","unstructured":"F. S. N. A. C. S. N. M. F. de L. M. M. F. C. I. S. S.-M. N. Andr\u00e9 de Almeida Campos L, Zein nanoparticles for drug delivery: Preparation methods and biological applications. Int J Pharm, 2023."},{"key":"1965_CR95","doi-asserted-by":"crossref","unstructured":"A. SSAGR, Iqbal HMAMAZ. O, Moxifloxacin loaded nanoparticles of disulfide bridged thiolated chitosan-eudragit RS100 for controlled drug delivery. Int J Biol Macromol, 2021.","DOI":"10.1016\/j.ijbiomac.2021.05.199"},{"key":"1965_CR96","doi-asserted-by":"crossref","unstructured":"McConnell SMAWBEL. An investigation into the digestion of Chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J Pharm Sci, 2008.","DOI":"10.1002\/jps.21271"},{"key":"1965_CR97","unstructured":"X. W. D. X. LHZJLCS, Yuan Y. Y, Fabrication and characterization of Zein nanoparticles by dextran sulfate coating as vehicles for delivery of Curcumin. Int J Biol Macromol, 2020."},{"key":"1965_CR98","doi-asserted-by":"publisher","unstructured":"Ziebarth J, et al. Oral delivery of Liraglutide-Loaded Zein\/Eudragit-Chitosan nanoparticles provides Pharmacokinetic and glycemic outcomes comparable to its subcutaneous injection in rats. Pharmaceutics. May 2024;16(5). https:\/\/doi.org\/10.3390\/pharmaceutics16050634","DOI":"10.3390\/pharmaceutics16050634"},{"key":"1965_CR99","doi-asserted-by":"publisher","unstructured":"Ismail R, Bocsik A, Katona G, Gr\u00f3f I, Deli MA, Cs\u00f3ka I. Encapsulation in polymeric nanoparticles enhances the enzymatic stability and the permeability of the glp-1 analog, liraglutide, across a culture model of intestinal permeability. Pharmaceutics. Nov. 2019;11(11). https:\/\/doi.org\/10.3390\/pharmaceutics11110599","DOI":"10.3390\/pharmaceutics11110599"},{"key":"1965_CR100","doi-asserted-by":"crossref","unstructured":"Yedi Herdiana NWSSMM. Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano, 7, 2022.","DOI":"10.1016\/j.onano.2022.100048"},{"key":"1965_CR101","doi-asserted-by":"crossref","unstructured":"Thapa KJO. RK, Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig, 2023.","DOI":"10.1007\/s40005-022-00607-6"},{"key":"1965_CR102","doi-asserted-by":"publisher","unstructured":"Jha SK et al. Dec., Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling, Journal of Controlled Release, vol. 328, pp. 368\u2013394, 2020, https:\/\/doi.org\/10.1016\/j.jconrel.2020.08.067","DOI":"10.1016\/j.jconrel.2020.08.067"},{"key":"1965_CR103","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.2147\/IJN.S442617","volume":"19","author":"S Kweon","year":"2024","unstructured":"Kweon S, et al. Coordinated ASBT and EGFR mechanisms for optimized liraglutide nanoformulation absorption in the GI tract. Int J Nanomed. 2024;19:2973\u201392. https:\/\/doi.org\/10.2147\/IJN.S442617","journal-title":"Int J Nanomed"},{"key":"1965_CR104","doi-asserted-by":"publisher","unstructured":"Bose A, Burman DR, Sikdar B, Patra P. Nanomicelles: Types, properties and applications in drug delivery, Feb. 01, 2021, John Wiley and Sons Inc. https:\/\/doi.org\/10.1049\/nbt2.12018","DOI":"10.1049\/nbt2.12018"},{"key":"1965_CR105","doi-asserted-by":"crossref","unstructured":"Subedi BAPSSJCSS. L, An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits., J Control Release., 2025.","DOI":"10.1016\/j.jconrel.2024.12.039"},{"key":"1965_CR106","doi-asserted-by":"publisher","unstructured":"Sharma V, Das Mukhopadhyay C. Exosome as drug delivery system: current advancements. Extracell Vesicle. Jun. 2024;3:100032. https:\/\/doi.org\/10.1016\/j.vesic.2023.100032","DOI":"10.1016\/j.vesic.2023.100032"},{"key":"1965_CR107","doi-asserted-by":"crossref","unstructured":"\u017d. PMK, Ku\u010duk LM. N, Exosomes engineering and their roles as therapy delivery tools, therapeutic targets, and biomarkers. Int J Mol Sci, 2021.","DOI":"10.3390\/ijms22179543"},{"key":"1965_CR108","doi-asserted-by":"crossref","unstructured":"West DW. Structure and function of the phosphorylated residues of casein. J Dairy Res, 1986.","DOI":"10.1017\/S0022029900024948"},{"key":"1965_CR109","doi-asserted-by":"publisher","unstructured":"Xu M, et al. Liraglutide-Loaded milk exosomes lower blood glucose when given by Sublingual route. ChemMedChem. May 2022;17(10). https:\/\/doi.org\/10.1002\/cmdc.202100758","DOI":"10.1002\/cmdc.202100758"},{"key":"1965_CR110","doi-asserted-by":"crossref","unstructured":"Khan SAJV. S, An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull, 2023.","DOI":"10.34172\/apb.2023.056"},{"key":"1965_CR111","doi-asserted-by":"crossref","unstructured":"Beloqui AMCDVKMGCPPV. A, A mechanistic study on Nanoparticle-Mediated Glucagon-Like Peptide-1 (GLP-1) secretion from enteroendocrine L cells. Mol Pharm, 2016.","DOI":"10.1021\/acs.molpharmaceut.6b00871"},{"key":"1965_CR112","doi-asserted-by":"publisher","unstructured":"Shrestha N, et al. The stimulation of GLP-1 secretion and delivery of GLP-1 agonists: via nanostructured lipid carriers. Nanoscale. Jan. 2018;10(2):603\u201313. https:\/\/doi.org\/10.1039\/c7nr07736j","DOI":"10.1039\/c7nr07736j"},{"key":"1965_CR113","doi-asserted-by":"publisher","unstructured":"Geng S, et al. Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo. Biomaterials. Apr. 2021;271. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120763","DOI":"10.1016\/j.biomaterials.2021.120763"},{"key":"1965_CR114","doi-asserted-by":"publisher","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications, May 01, 2022, Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394","DOI":"10.1016\/j.heliyon.2022.e09394"},{"key":"1965_CR115","doi-asserted-by":"crossref","unstructured":"Jha SPMR. S, Liposomal drug delivery system for cancer therapy: advancement and patents. Recent Pat Drug Deliv Formul, 2016.","DOI":"10.2174\/1872211310666161004155757"},{"key":"1965_CR116","unstructured":"D. Y. M. ZYPBH, X. Y, Sun T. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl, 2014."},{"key":"1965_CR117","unstructured":"J. D. A. JFS. T. K. B. B. Gavin T. Noble, Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol, 2014."},{"key":"1965_CR118","unstructured":"Hafner A;LJLGPPI. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomed."},{"key":"1965_CR119","doi-asserted-by":"crossref","unstructured":"U. DSK. N.&, Bulbake KW. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, Pharmaceutics, 2017.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"1965_CR120","doi-asserted-by":"publisher","unstructured":"Zhang L, Ding L, Tang C, Li Y, Yang L. Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes, Drug Deliv, vol. 23, no. 9, pp. 3358\u20133363, Nov. 2016, https:\/\/doi.org\/10.1080\/10717544.2016.1180723","DOI":"10.1080\/10717544.2016.1180723"},{"key":"1965_CR121","doi-asserted-by":"publisher","unstructured":"Ding R, et al. Preparation, drug distribution, and in vivo evaluation of the safety of protein Corona liposomes for liraglutide delivery. Nanomaterials. Feb. 2023;13(3). https:\/\/doi.org\/10.3390\/nano13030540","DOI":"10.3390\/nano13030540"},{"key":"1965_CR122","doi-asserted-by":"crossref","unstructured":"de Silva MDOVCA. RYP, Microparticles in the development and improvement of pharmaceutical formulations: an analysis of in vitro and in vivo studies. Int J Mol Sci, 2023.","DOI":"10.3390\/ijms24065441"},{"key":"1965_CR123","doi-asserted-by":"crossref","unstructured":"A. A. I. Lengyel K-SNAVL. M, Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci Pharm, 2019.","DOI":"10.3390\/scipharm87030020"},{"key":"1965_CR124","doi-asserted-by":"publisher","unstructured":"Wu J, Williams GR, Branford-White C, Li H, Li Y, Zhu LM. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation. Eur J Pharm Sci. Sep. 2016;92:28\u201338. https:\/\/doi.org\/10.1016\/j.ejps.2016.06.018","DOI":"10.1016\/j.ejps.2016.06.018"},{"key":"1965_CR125","doi-asserted-by":"publisher","unstructured":"Gao Z, et al. Development of 1 month Sustained-Release microspheres containing liraglutide for type 2 diabetes treatment. ACS Appl Mater Interfaces. May 2024;16:25869\u201378. https:\/\/doi.org\/10.1021\/acsami.4c04010","DOI":"10.1021\/acsami.4c04010"},{"key":"1965_CR126","doi-asserted-by":"crossref","unstructured":"Ho CC. TC, Hydrogels: Properties and Applications in Biomedicine., Molecules, 2022.","DOI":"10.3390\/molecules27092902"},{"key":"1965_CR127","doi-asserted-by":"crossref","unstructured":"Narayanaswamy TVP. R, Hydrogels and their applications in targeted drug delivery. Molecules, 2019.","DOI":"10.1201\/9780429295010-35"},{"key":"1965_CR128","doi-asserted-by":"crossref","unstructured":"Nikouei GNLA. NS, Temperature\/pH responsive hydrogels based on Poly(ethylene glycol) and Functionalized Poly(e-caprolactone) Block Copolymers for Controlled Delivery of Macromolecules. Pharm Res, 2016.","DOI":"10.1007\/s11095-015-1794-z"},{"key":"1965_CR129","doi-asserted-by":"publisher","unstructured":"Chen Y, Luan J, Shen W, Lei K, Yu L, Ding J. Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System, ACS Appl Mater Interfaces, vol. 8, no. 45, pp. 30703\u201330713, Nov. 2016, https:\/\/doi.org\/10.1021\/acsami.6b09415","DOI":"10.1021\/acsami.6b09415"},{"key":"1965_CR130","doi-asserted-by":"crossref","unstructured":"Petit HWE. Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomaterials, 2014.","DOI":"10.1016\/j.biomaterials.2014.05.064"},{"key":"1965_CR131","doi-asserted-by":"crossref","unstructured":"Vermonden CRHWE. T, Hydrogels for protein delivery. Chem Rev, 2012.","DOI":"10.1021\/cr200157d"},{"key":"1965_CR132","doi-asserted-by":"crossref","unstructured":"Huang LZCDHCCYSHW. CC, Injectable cell constructs fabricated via culture on a thermoresponsive Methylcellulose hydrogel system for the treatment of ischemic diseases. Adv Healthc Mater, 2014.","DOI":"10.1002\/adhm.201300605"},{"key":"1965_CR133","doi-asserted-by":"crossref","unstructured":"Fu KWJ. Y, In situ forming poly(ethylene glycol)-based hydrogels via thiol-maleimide Michael-type addition. J Biomed Mater Res A, 2011.","DOI":"10.1002\/jbm.a.33106"},{"key":"1965_CR134","doi-asserted-by":"crossref","unstructured":"Park JMCBJB. MH, Biodegradable thermogels. Acc Chem Res, 2012.","DOI":"10.1021\/ar200162j"},{"key":"1965_CR135","doi-asserted-by":"crossref","unstructured":"Ci CLYLDJ. T, Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel. Sci Rep, 2014.","DOI":"10.1038\/srep05473"},{"key":"1965_CR136","unstructured":"Z. DJZ, Li YMYJWJCFCX. X, Kartogenin-Incorporated thermogel supports stem cells for significant cartilage regeneration. ACS Appl Mater Interfaces, 2016."},{"key":"1965_CR137","doi-asserted-by":"crossref","unstructured":"A. A. W. J. VMBMUL, Safaei Nikouei LA. N, Thermoreversible hydrogels based on triblock copolymers of poly(ethylene glycol) and carboxyl functionalized poly(\u03b5-caprolactone): the effect of carboxyl group substitution on the transition temperature and biocompatibility in plasma. Acta Biomater, 2015.","DOI":"10.1016\/j.actbio.2014.10.001"},{"key":"1965_CR138","doi-asserted-by":"crossref","unstructured":"Nguyen LDS. MK, Injectable biodegradable hydrogels. Macromol Biosci, 2010.","DOI":"10.1002\/mabi.200900402"},{"key":"1965_CR139","doi-asserted-by":"crossref","unstructured":"Boffito SPDRACV. M, Thermosensitive block copolymer hydrogels based on poly(\u025b-caprolactone) and polyethylene glycol for biomedical applications: state of the Art and future perspectives. J Biomed Mater Res A, 2015.","DOI":"10.1002\/jbm.a.35253"},{"key":"1965_CR140","doi-asserted-by":"publisher","unstructured":"Usach I, Martinez R, Festini T, Peris J-E. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site, Adv Ther, vol. 36, no. 11, pp. 2986\u20132996, Nov. 2019, https:\/\/doi.org\/10.1007\/s12325-019-01101-6","DOI":"10.1007\/s12325-019-01101-6"},{"key":"1965_CR141","unstructured":"K. D. GSS. M. M. P. G. G. M. S. K. D. Tejashree Waghule, Microneedles: A smart approach and increasing potential for transdermal drug delivery system, Biomedicine & Pharmacotherapy, 2019."},{"key":"1965_CR142","unstructured":"K. H. SJJSJPMJG. Y. H. S. M. J. S. S. L. H. W. K. H. J. Jeongyun you, egg microneedle for transdermal delivery of active liraglutide. Adv Healthc Mater, 2023."},{"key":"1965_CR143","doi-asserted-by":"publisher","unstructured":"Rabiei M, et al. Dissolving microneedle-assisted long-acting liraglutide delivery to control type 2 diabetes and obesity. Eur J Pharm Sci. Dec. 2021;167. https:\/\/doi.org\/10.1016\/j.ejps.2021.106040","DOI":"10.1016\/j.ejps.2021.106040"},{"key":"1965_CR144","unstructured":"Y. LJHY, Z. H. J. Y. J. C. H. Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs., Drug Deliv Transl Res., 2025."},{"key":"1965_CR145","unstructured":"J. JS, Y. J. P. H. YMJG, K. J. S. H. W. K. and, Seorin HJ, Juhng. Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity, Lab Chip, 2023."},{"key":"1965_CR146","doi-asserted-by":"publisher","unstructured":"Shamekhi F, Tamjid E, Khajeh K. Development of Chitosan coated calcium-alginate nanocapsules for oral delivery of liraglutide to diabetic patients. Int J Biol Macromol. Dec. 2018;120:460\u20137. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.078. Pt A.","DOI":"10.1016\/j.ijbiomac.2018.08.078"},{"key":"1965_CR147","doi-asserted-by":"publisher","unstructured":"Uhl P, et al. Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine. Feb. 2020;24:102132. https:\/\/doi.org\/10.1016\/j.nano.2019.102132","DOI":"10.1016\/j.nano.2019.102132"},{"key":"1965_CR148","doi-asserted-by":"publisher","unstructured":"Ismail R, et al. Synthesis and statistical optimization of Poly (Lactic-Co-Glycolic Acid) nanoparticles encapsulating GLP1 analog designed for oral delivery. Pharm Res. Jul. 2019;36:1\u201316. https:\/\/doi.org\/10.1007\/s11095-019-2620-9","DOI":"10.1007\/s11095-019-2620-9"},{"key":"1965_CR149","doi-asserted-by":"publisher","unstructured":"He M, Fang M, Fan L, Maimaitijiang A. Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis, J Nanobiotechnology, vol. 22, no. 1, pp. 1\u201317, Dec. 2024, https:\/\/doi.org\/10.1186\/s12951-024-02775-z","DOI":"10.1186\/s12951-024-02775-z"},{"key":"1965_CR150","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.2147\/IJN.S413515","volume":"18","author":"JG Song","year":"2023","unstructured":"Song JG, Kim DH, Han HK. Fabrication and evaluation of a pH-Responsive Nanocomposite-Based colonic delivery system for improving the oral efficacy of liraglutide. Int J Nanomed. 2023;18:3937\u201349. https:\/\/doi.org\/10.2147\/IJN.S413515","journal-title":"Int J Nanomed"},{"key":"1965_CR151","doi-asserted-by":"crossref","unstructured":"Avcil \u00c7A. M, Microneedles in Drug Delivery: Progress and Challenges. Micromachines (Basel)., 2021.","DOI":"10.3390\/mi12111321"},{"key":"1965_CR152","doi-asserted-by":"crossref","unstructured":"Lee PJPMR. JW, Dissolving microneedles for transdermal drug delivery. Biomaterials, 2008.","DOI":"10.1016\/j.biomaterials.2007.12.048"},{"key":"1965_CR153","doi-asserted-by":"crossref","unstructured":"Adhikari GJCSRPMMI. BB, Assessing the potential Cost-Effectiveness of microneedle patches in childhood measles vaccination programs: the case for further research and development. Drugs R D, 2016.","DOI":"10.1007\/s40268-016-0144-x"},{"key":"1965_CR154","doi-asserted-by":"crossref","unstructured":"Liu CK. B, Advances in Hydrogel-Based drug delivery systems. Gels, 2024.","DOI":"10.3390\/gels10040262"},{"key":"1965_CR155","unstructured":"Liraglutide. (Victoza)."},{"key":"1965_CR156","doi-asserted-by":"publisher","unstructured":"Zinman B et al. Jul., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\u2009+\u2009TZD), Diabetes Care, vol. 32, no. 7, pp. 1224\u20131230, 2009, https:\/\/doi.org\/10.2337\/dc08-2124","DOI":"10.2337\/dc08-2124"},{"key":"1965_CR157","doi-asserted-by":"publisher","unstructured":"Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0\u00a0mg of Liraglutide in Weight Management, New England Journal of Medicine, vol. 373, no. 1, pp. 11\u201322, Jul. 2015, https:\/\/doi.org\/10.1056\/nejmoa1411892","DOI":"10.1056\/nejmoa1411892"},{"key":"1965_CR158","doi-asserted-by":"publisher","unstructured":"Davies MJ et al. Aug., Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial, JAMA -Journal of the American Medical Association, vol. 314, no. 7, pp. 687\u2013699, 2015, https:\/\/doi.org\/10.1001\/jama.2015.9676","DOI":"10.1001\/jama.2015.9676"},{"key":"1965_CR159","doi-asserted-by":"publisher","unstructured":"Liraglutide and cardiovascular outcomes in type 2 diabetes, 2016, BMJ Publishing Group. https:\/\/doi.org\/10.1056\/nejmoa1603827","DOI":"10.1056\/nejmoa1603827"},{"key":"1965_CR160","doi-asserted-by":"publisher","unstructured":"Davies MJ, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care. Feb. 2016;39(2):222\u201330. https:\/\/doi.org\/10.2337\/dc14-2883","DOI":"10.2337\/dc14-2883"},{"key":"1965_CR161","doi-asserted-by":"publisher","unstructured":"Kelly AS, et al. Controlled trial of liraglutide for adolescents with obesity. N Engl J Med. May 2020;382:2117\u201328. https:\/\/doi.org\/10.1056\/nejmoa1916038. A Randomized.","DOI":"10.1056\/nejmoa1916038"},{"key":"1965_CR162","unstructured":"Fda, HIGHLIGHTS OF PRESCRIBING INFORMATION., Accessed: Feb. 22, 2025. [Online]. Available: www.fda.gov\/medwatch"},{"key":"1965_CR163","unstructured":"fda, cder, HIGHLIGHTS OF PRESCRIBING INFORMATION., Accessed: Feb. 22, 2025. [Online]. Available: www.fda.gov\/medwatch"},{"key":"1965_CR164","doi-asserted-by":"publisher","unstructured":"D\u2019Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity, Cardiol Rev, vol. 32, no. 1, pp. 83\u201390, Jan. 2024, https:\/\/doi.org\/10.1097\/CRD.0000000000000513","DOI":"10.1097\/CRD.0000000000000513"},{"key":"1965_CR165","unstructured":"Ph. MDHSBMDCB, Melanie DAEMDPDWT, Davies J. Cagrilintide\u2013Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes, N Engl J Med, Jun. 2025."},{"key":"1965_CR166","doi-asserted-by":"publisher","unstructured":"Jastreboff AM et al. Aug., Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial, New England Journal of Medicine, vol. 389, no. 6, pp. 514\u2013526, 2023, https:\/\/doi.org\/10.1056\/nejmoa2301972","DOI":"10.1056\/nejmoa2301972"},{"key":"1965_CR167","doi-asserted-by":"publisher","unstructured":"Wharton S et al. Sep., Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, New England Journal of Medicine, vol. 389, no. 10, pp. 877\u2013888, 2023, https:\/\/doi.org\/10.1056\/nejmoa2302392","DOI":"10.1056\/nejmoa2302392"},{"key":"1965_CR168","doi-asserted-by":"publisher","unstructured":"Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists, Sep. 26, 2015, Springer Healthcare. https:\/\/doi.org\/10.1007\/s13300-015-0127-x","DOI":"10.1007\/s13300-015-0127-x"},{"key":"1965_CR169","doi-asserted-by":"crossref","unstructured":"Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes, 2005. [Online]. Available: http:\/\/diabetesjournals.org\/care\/article-pdf\/28\/5\/1092\/566577\/zdc00505001092.pdf","DOI":"10.2337\/diacare.28.5.1092"},{"key":"1965_CR170","doi-asserted-by":"publisher","unstructured":"Bain SC. The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist, Dec. 01, 2014, Springer Healthcare. https:\/\/doi.org\/10.1007\/s13300-014-0073-z","DOI":"10.1007\/s13300-014-0073-z"},{"key":"1965_CR171","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","author":"DG B.-F. K. K. P. M. J. N","year":"2016","unstructured":"B.-F. K. K. P. M. J. N. DG. M. N. S. P. S. P. N. R. L. S. W. S. M. Z. B. B. R. B. J. L. S. C. Marso SP, liraglutide and cardiovascular outcomes in type 2 diabetes. BMJ Publishing Group. 2016. https:\/\/doi.org\/10.1056\/nejmoa1603827","journal-title":"BMJ Publishing Group"},{"issue":"3","key":"1965_CR172","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"Frias JP, et al. Efficacy and safety of dulaglutide 3.0\u00a0mg and 4.5\u00a0mg versus dulaglutide 1.5\u00a0mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (award-11). Diabetes Care. 2021;44(3):765\u201373. https:\/\/doi.org\/10.2337\/dc20-1473","journal-title":"Diabetes Care"},{"key":"1965_CR173","doi-asserted-by":"publisher","unstructured":"Cherney DZI et al. Nov., Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs, Kidney Int Rep, vol. 7, no. 11, pp. 2345\u20132355, 2022, https:\/\/doi.org\/10.1016\/j.ekir.2022.07.167","DOI":"10.1016\/j.ekir.2022.07.167"},{"key":"1965_CR174","doi-asserted-by":"crossref","unstructured":"Dahl OYNPHRBRPHR. D, Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial., JAMA, 2022.","DOI":"10.1001\/jama.2022.0078"},{"key":"1965_CR175","doi-asserted-by":"publisher","unstructured":"Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. Aug. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/nejmoa1616011","DOI":"10.1056\/nejmoa1616011"},{"key":"1965_CR176","doi-asserted-by":"crossref","unstructured":"Kohut PJ. T, Liraglutide with lifestyle intervention in adolescents with overweight\/obesity, nonalcoholic fatty liver disease, and type II diabetes mellitus. JPGN Rep, 2021.","DOI":"10.1097\/PG9.0000000000000141"},{"key":"1965_CR177","doi-asserted-by":"publisher","unstructured":"Torbahn G et al. Pharmacological interventions for the management of children and adolescents living with obesity\u2014An update of a Cochrane systematic review with meta-analyses, May 01, 2024, John Wiley and Sons Ltd. https:\/\/doi.org\/10.1111\/ijpo.13113","DOI":"10.1111\/ijpo.13113"},{"key":"1965_CR178","unstructured":"US-FDA. FDA approves weight management drug for patients aged 12 and older, 2023."},{"key":"1965_CR179","unstructured":"Semaglutide WP, Kommu S. Semaglutide, StatPearls Publishing, 2024."},{"key":"1965_CR180","unstructured":"SingleCare, Team. How much is Victoza without insurance? The Checkup."},{"key":"1965_CR181","unstructured":"Pharmaceuticals T. Teva Announces Launch of Authorized Generic of Victoza\u00ae (liraglutide injection 1.8\u00a0mg), in the United States."},{"key":"1965_CR182","unstructured":"Hikma. Hikma receives FDA approval and launches the generic version of Victoza\u00ae, Liraglutide, in the US."},{"key":"1965_CR183","unstructured":"Biocon. Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K."},{"key":"1965_CR184","doi-asserted-by":"crossref","unstructured":"Hunter HC. K, Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci, 2012.","DOI":"10.1186\/1471-2202-13-33"},{"key":"1965_CR185","doi-asserted-by":"crossref","unstructured":"Kalinderi PVFL. K, GLP-1 receptor agonists: A new treatment in parkinson\u2019s disease. Int J Mol Sci, 2024.","DOI":"10.20944\/preprints202402.1245.v1"},{"key":"1965_CR186","unstructured":"Health F. Fractyl Health Advances Rejuva\u00ae Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes, 2025. [Online]. Available: www.fractyl.com."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01965-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:05:04Z","timestamp":1763413504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01965-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":186,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01965-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}